Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12440950 | 0.81 | ALDH1A3 (0.38) | ALDH1A3TYRERN1CYP1A2MAPT | |
| SCHEMBL13429930 | 0.80 | ALDH1A3 (0.37) | ALDH1A3TYRERN1CYP1A2MAPT | |
| SCHEMBL16687422 | 0.79 | ALDH1A3 (0.36) | ALDH1A3TYRERN1 | |
| SCHEMBL12514805 | 0.79 | ALDH1A3 (0.36) | ALDH1A3TYRERN1LMNA | |
| SCHEMBL27775328 | 0.76 | CA1 (0.43) | ALDH1A3ERN1CYP1A2MAPTCYP2C9 | |
| SCHEMBL16098198 | 0.70 | MAPT (0.42) | ERN1MAPTCYP2C9CYP2C19LMNA | |
| SCHEMBL38651684 | 0.70 | ALDH1A3 (0.37) | ALDH1A3TYRERN1CYP1A2MAPT | |
| SCHEMBL8940219 | 0.69 | ERN1 (0.43) | ALDH1A3ERN1CYP1A2MAPTCYP2C9 | |
| SCHEMBL22011034 | 0.69 | CA1 (0.43) | ALDH1A3ERN1CYP1A2MAPTCYP2C9 | |
| SCHEMBL9946014 | 0.68 | ALDH1A3 (0.42) | ALDH1A3TYRERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ALDH1A3 2559/4885TYR 2328/4885ERN1 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.